SHANGHAI, Aug. 16, 2024 /PRNewswire/ — On August 16, 2024 (local time), Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. officially announced the launch of the “Sanyou Innovative Intelligent Antibody Design oneClick+ Platform.” Sanyou Bio’s Innovative Intelligent Antibody Design oneClick+ Platform, independently designed by Sanyou Bio, integrates 90% of the mainstream antibody structures currently available on the market and […]
Category Archives: Pr Newswire
LOS ANGELES, Aug. 16, 2024 /PRNewswire/ — Prime Focus Technologies (PFT), a pioneer in AI-powered technology solutions, unveils CLEAR® AI Agents at IBC 2024 in Amsterdam. These are designed to assist & co-work with professionals within Media & Entertainment (M&E) enterprises to execute specific tasks across content management, postproduction, and marketing. The agents seamlessly handle repetitive tasks, […]
SHANGHAI, Aug. 16, 2024 /PRNewswire/ — XChange TEC.INC (NASDAQ: XHG) (the “Company”), today announced that it received two letters, dated August 12 and 14, 2024, respectively, from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it had regained compliance with the requirement to maintain a minimum bid price of $1 per share as set […]
Pr Newswire
Pathos Expands Pipeline With Worldwide License of Phase 2-ready Brain-penetrant, PRMT5 Inhibitor
15
Aug
Aug
CHICAGO, Aug. 15, 2024 (GLOBE NEWSWIRE) — Pathos AI, Inc. (www.pathos.com), a biotechnology company focused on revolutionizing precision medicine in cancer by harnessing the power of machine learning to transform drug development, announced today the world-wide license of PRT811, a potent, selective, and orally bioavailable brain penetrant SAM-competitive PRMT5 inhibitor from Prelude Therapeutics. PRT811 (renamed […]
Pr Newswire
DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function
15
Aug
Aug
TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) — DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is offering its novel BRAIN AGE® Brain Health AI Platform (“BRAIN AGE®”) as a clinical tool for investigating the impact of weight loss drugs, such as Semaglutide, […]
Pr Newswire
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
15
Aug
Aug
Broad agreement on pivotal Phase 3 study plan, including use of current amezalpat dose and schedule Overall survival, the strongest result from the Phase 2 trial, will be the primary study endpoint Agreed-upon early efficacy analysis could reduce time to primary read-out significantly BRISBANE, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: […]
15
Aug
Aug
Hear from Former CDC Director and Visionary Executives from AWS, Oracle Cloud Infrastructure, Snowflake, and Many Other Organizations on the Forefront of Data-Driven Healthcare BOWIE, Md., Aug. 15, 2024 (GLOBE NEWSWIRE) — Inovalon, a leading provider of cloud-based software solutions empowering data-driven healthcare, today announced Empower will return this fall to captivate key stakeholders from […]
15
Aug
Aug
Next-generation robotics company to share field results, deliver interactive simulations and host multiple events for its Galaxy System at leading bronchology and pulmonology gathering SAN CARLOS, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) — Medical robotics innovator Noah Medical will feature prominently at this year’s American Association for Bronchology and Interventional Pulmonology’s annual conference (AABIP 2024) […]
HONG KONG, Aug. 15, 2024 /PRNewswire/ — China Merchants Commercial Real Estate Investment Trust (“CMC REIT” or “the Trust”, HKEX stock code:1503), announced its interim results for the six months ended 30 June 2024. Despite a challenging environment, CMC REIT delivered strong operating performance during the period. Due to a significant increase of 9.7% in […]
Total revenues decreased by 20.5% year over year to RMB 329.7million (US$45.4 million)[1]. Income from operations was RMB84.4 million (US$11.6 million)[1] compared to RMB98.6 million for the second quarter of 2023. Net income was RMB62.3 million (US$8.6 million)[1] compared to RMB101.9 million for the second quarter of 2023. Adjusted EBITDA (non-GAAP)[2] decreased 34.5% year over year to RMB83.1 million (US$11.4 million)[1]. Core net income (non-GAAP)[3] increased 2.4% year over year […]